66 results
144
Dananberg Jamie
1 Oct 21
Notice of proposed sale of securities
9:49pm
to the payment of all or any part of the purchase price or other consideration therefor:
Title of
the Class
Date you
Acquired
Nature of Acquisition … Transaction
Name of Person from Whom Acquired
(If gift, also give date donor acquired)
Amount of
Securities Acquired
Date of
Payment
Nature
8-K
UBX
Unity Biotechnology Inc
4 Aug 20
Unity Biotechnology Announces $80M Debt Financing from Hercules Capital
4:15pm
insurance coverage. The negative covenants include, among others, restrictions on the Company’s transferring collateral, making changes to the nature … . Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the satisfaction of closing conditions
8-K
UBX
Unity Biotechnology Inc
16 Sep 20
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology
4:49pm
impact of the restructuring plan. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include
8-K
EX-99.1
ay8sc09wz d94zne9
30 Mar 20
UNITY Biotechnology Announces Start of New CEO and New Employment Inducement Grants
5:05pm
8-K
o6s8thlle8z7rs9g8juz
17 Aug 20
UNITY Biotechnology Announces 12-week data from UBX0101 Phase 2 Clinical Study in Patients with Painful Osteoarthritis of the Knee
4:45pm
8-K
EX-99.1
ry3sdm3 s1lvb
22 Aug 22
UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering
4:13pm
8-K
1fufdwwd6v52ac30t
19 Oct 22
Material Modifications to Rights of Security Holders
5:06pm
8-K
EX-99.1
0vvlbyqprv
19 Oct 22
Material Modifications to Rights of Security Holders
5:06pm
8-K
EX-99.1
w7xawp
15 Apr 24
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
7:00am
D
5qo993x
5 May 09
Exempt offering of security
12:00am
D
dodsgr1 gt2bwu0m76
5 May 09
Exempt offering of security
12:00am
D
uejuc83 v4wazot
15 Jul 13
$6.08M in equity / options / securities to be acquired, sold $2.04M, 4 investors
12:00am
8-K
EX-99.1
rqjeyai
1 Nov 22
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:00am
8-K
EX-99.1
v3tzg7xobf0
7 May 20
UNITY Biotechnology, Inc. Reports First Quarter 2020 Financial Results and Business Updates
4:07pm
8-K
EX-99.1
1q69 modo7
12 Aug 22
UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:18am